| Outcomes | N(n) | Effect estimate (95%CI) | I2 | Interaction P |
| Blood loss within 2 hours after delivery (mL) | | Overall | 29 (6060) | -55.06 (-84.06, -26.06) | 100% | | Type of administration | | | | | Immediate administration | 18 (4297) | -45.91 (-87.57, -4.25) | 100% | 0.33 | Consecutive administration | 11 (1763) | -69.93 (-93.59, -46.27) | 99% | | Risk factor for PPH | | | | | No risk factor | 12 (3460) | -69.33 (-108.01, -30.64) | 100% | 0.007 | High risk factor | 6 (870) | -71.66 (-103.41, -39.92) | 97% | | Unclear | 11 (1730) | -29.15 (-36.81, -21.49) | 98% | | Blood loss within 24 hours after delivery (mL) | | Overall | 27 (5710) | -85.57 (-94.26, -76.88) | 95% | | Type of administration | | | | | Immediate administration | 17 (4043) | -93.61 (-109.52, -77.69) | 98% | 0.21 | Consecutive administration | 10 (1667) | -80.91 (-92.61, -69.21) | 88% | | Risk factor for PPH | | | | | No risk factor | 11 (3206) | -80.90 (-94.98, -66.82) | 96% | 0.63 | High risk factor | 6 (870) | -84.72 (-98.01, -71.43) | 61% | | Unclear | 10 (1634) | -91.82 (-109.22, -74.43) | 96% | | Postpartum hemorrhage | | Overall | 18 (4767) | 0.29 (0.21, 0.39) | 0% | | Type of administration | | | | | Immediate administration | 12 (3523) | 0.30 (0.21, 0.42) | 0% | 0.62 | Consecutive administration | 6 (1244) | 0.24 (0.12, 0.51) | 0% | | Risk factor for PPH | | | | | No risk factor | 8 (2811) | 0.29 (0.18, 0.44) | 0% | 0.97 | High risk factor | 5 (820) | 0.27 (0.14, 0.51) | 0% | | Unclear | 5 (1136) | 0.31 (0.16, 0.57) | 0% | | Adverse events | | Overall | 21 (4793) | 0.53 (0.40, 0.70) | 54% | | Type of administration | | | | | Immediate administration | 15 (3653) | 0.74 (0.54, 1.03) | 0 | <0.001 | Consecutive administration | 6 (1140) | 0.19 (0.11, 0.33) | 35% | | Risk factor for PPH | | | | | No risk factor | 10 (2987) | 0.60 (0.42, 0.85) | 77% | 0.88 | High risk factor | 3 (350) | 0.66 (0.18, 2.34) | — | | Unclear | 8 (1456) | 0.51 (0.30, 0.87) | 0% | |
|
|